Results 31 to 40 of about 302,754 (340)

Systematic review of efficacy, safety and pharmacokinetics of intravenous and intraventricular vancomycin for central nervous system infections

Frontiers in Pharmacology, 2022
Objective: The decision of vancomycin dosage for central nervous system (CNS) infections is still a challenge because its bactericidal nature in cerebrospinal fluid (CSF) has not been confirmed by human studies.
Shu-Ping Liu, Jing Xiao, Ya-Li Liu, Yue-E Wu, Hui Qi, Zhuang-Zhuang Wang, A-Dong Shen, A-Dong Shen, Gang Liu, Wei Zhao, Wei Zhao   +10 more
doaj   +1 more source

Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit

Frontiers in Pediatrics, 2022
ObjectiveTo explore the efficacy and safety of vancomycin as measured by pharmacokinetic/pharmacodynamic parameters in children with severe infection in the Pediatric Intensive Care Unit (PICU) and to determine the appropriate threshold for avoiding ...
Bo Zhou, Bo Zhou, Bo Zhou, Bo Zhou, Wenyi Xiong, Ke Bai, Ke Bai, Ke Bai, Ke Bai, Hongxing Dang, Hongxing Dang, Hongxing Dang, Hongxing Dang, Jing Li, Jing Li, Jing Li, Jing Li, Feng Xu, Feng Xu, Feng Xu, Feng Xu, Yue-qiang Fu, Yue-qiang Fu, Yue-qiang Fu, Yue-qiang Fu, Chengjun Liu, Chengjun Liu, Chengjun Liu, Chengjun Liu   +28 more
doaj   +1 more source

Acute kidney injury following the concurrent administration of antipseudomonal beta-lactams and vancomycin: a network meta-analysis.

Clinical Microbiology and Infection, 2020
BACKGROUND AND OBJECTIVES Acute kidney injury represents a major complication of vancomycin treatment, especially when it is co-administered with other nephrotoxins.
I. Bellos, V. Karageorgiou, V. Pergialiotis, D. Perrea   +3 more
semanticscholar   +1 more source

Optimizing Guideline-Recommended Antibiotic Doses for Pediatric Infective Endocarditis [PDF]

, 2016
The American Heart Association recently published an updated scientific statement on the management of infective endocarditis in childhood. The recommendations included for vancomycin, aminoglycoside, and β-lactam dosing and monitoring are based ...
Israel, Emily N., Knoderer, Chad A., Nichols, Kristen R., Thomas, Christopher A.   +3 more
core   +3 more sources

Risk of vancomycin-resistant enterococci bloodstream infection among patients colonized with vancomycin-resistant enterococci

Brazilian Journal of Infectious Diseases, 2015
Background: Vancomycin-resistant enterococci colonization has been reported to increase the risk of developing infections, including bloodstream infections.
Ahu Kara, İlker Devrim, Nuri Bayram, Nagehan Katipoğlu, Ezgi Kıran, Yeliz Oruç, Nevbahar Demiray, Hurşit Apa, Gamze Gülfidan   +8 more
doaj   +1 more source

Vancomycin Therapeutic Drug Monitoring (TDM) and Its Association with Clinical Outcomes: A Retrospective Cohort

Journal of Infection and Public Health, 2022
Background: Therapeutic drug monitoring (TDM) has proven effectiveness in maintaining efficacy and reducing toxicities associated with vancomycin. A trough level of (15–20 mg/L) for MRSA serious infections is recommended.
Juhaina Salim Al-Maqbali, Zahra Al Shukri, Nawf Al Sabahi, Intisar AL-Riyami, Abdullah M. Al Alawi   +4 more
doaj   +1 more source

Vancomycin-resistantEnterococcus

Swiss Medical Weekly, 2012
The reported prevalence of vancomycin-resistant Enterococcus faecium (VRE) in Switzerland for the years 2008–2010 has been low at <5%. At the University Hospital Zurich, 17 cases of VRE were detected between 28 December 2009 and 15 February 2010. Nine cases were diagnosed clinically; eight cases were detected by rectal screening. The centre of
Thierfelder, C, Keller, P M, Kocher, C, Gaudenz, R, Hombach, M, Bloemberg, G V, Ruef, C   +6 more
openaire   +4 more sources

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital

International Journal of Pediatrics, 2018
Background. Vancomycin and piperacillin-tazobactam (PTZ) are commonly used as empirical therapy for patients with health care associated infections. Vancomycin has been recognized as a nephrotoxic agent and in a few cases in the literature PTZ has been ...
Mohammed Al Nuhait, Laila C. Abu Esba, Khalid Al Harbi, Meshary Al Meshary, Rami T. Bustami   +4 more
doaj   +1 more source

Impact of time to appropriate therapy on mortality in patients with vancomycin-intermediate Staphylococcus aureus infection [PDF]

, 2016
Despite the increasing incidence of vancomycin-intermediate Staphylococcus aureus (VISA) infections, few studies have examined the impact of delay in receipt of appropriate antimicrobial therapy on outcomes in VISA patients.
Burnham, Carey-Ann D, Burnham, Jason P, Kollef, Marin H, Warren, David K   +3 more
core   +2 more sources

Risk factors for vancomycin treatment failure in heterogeneous vancomycin-intermediate Staphylococcus aureus bacteremia

Microbiology Spectrum
The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) infection is increasing and is associated with vancomycin treatment failures.
Ji Hyun Yun, Euijin Chang, Seongman Bae, Jiwon Jung, Min Jae Kim, Yong Pil Chong, Sung-Han Kim, Sang-Ho Choi, Sang-Oh Lee, Yang Soo Kim   +9 more
doaj   +1 more source